Press Releases

Month Year

Month Year

Jan 25, 2023

NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
Jan 25, 2023

FDA approves expanded label of Enjaymo® (sutimlimab-jome) to include long-term safety and efficacy for people with cold agglutinin disease
Jan 18, 2023

Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
Jan 17, 2023

FDA approves Adacel® for immunization during pregnancy to help protect young infants against pertussis
Dec 21, 2022

Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo

Show per page

Print
Email page
RSS